Core Viewpoint - The keyword for the stock market in 2025 is expected to be "innovative drugs," with significant stock price increases driven by the potential of in-development innovative drugs and BD (business development) transactions rather than traditional revenue from already marketed drugs [1] Group 1: BD Transactions - In 2025, China's innovative drug BD transaction total exceeded $100 billion, with notable orders reaching $10 billion, and upfront payments from multinational pharmaceutical companies reaching a new high of $1.25 billion [1] - Landmark transactions include a $13 billion collaboration between Qihuang Dejian and Biohaven/AimedBio in January, marking a milestone for China's ADC technology [2] - In May, 3SBio's deal with Pfizer exceeded $6 billion, setting a record for upfront payments in China at $1.25 billion, highlighting the value of both first-in-class and fast-follow drugs [2] - In July, a $12 billion strategic partnership between Hengrui Medicine and GlaxoSmithKline showcased the depth of early-stage pipelines in leading Chinese pharmaceutical companies [2] - In October, Innovent Biologics and Takeda's collaboration worth $11.4 billion included a cost-sharing model for global R&D, enhancing operational capabilities for future international ventures [2] Group 2: Milestone Payments and Emerging Fields - Several past BD transactions reached milestone payments in 2025, including a $300 million payment to China National Pharmaceutical's subsidiary from Merck and a $250 million payment to Bairui Tianheng from Bristol-Myers Squibb [3] - The focus of BD transactions is shifting from oncology to other therapeutic areas, with autoimmune diseases, metabolism, and central nervous system disorders emerging as new hot fields [3] - Notable deals include the global rights licensing of BTK inhibitor Orelabrutinib for multiple sclerosis by Nocera Biopharma, with a potential total transaction value exceeding $2 billion [3] - The metabolic field is gaining traction, driven by global weight loss trends, with several companies entering into licensing agreements for GLP-1 targeted drugs [3] Group 3: Independent Clinical Trials and Regulatory Approvals - Numerous innovative drug companies in China are advancing their own overseas clinical trials, achieving significant progress [4] - In early 2025, Dize Pharmaceutical's lung cancer targeted drug received priority review from the FDA and was approved in July, becoming the first globally innovative drug independently developed in China to gain approval in the U.S. [4] - Other advancements include breakthrough therapy designations for CS0159 by Kexi Kedi and a Phase III trial approval for a recombinant human albumin injection by Heyuan Biopharma [4] - These developments indicate that the Chinese innovative drug industry is becoming a significant force in global innovation, transitioning from fast-following to original innovation and integrating deeply into the global value chain [4]

经济观察报 记者 刘晓诺 2025年中国创新药的BD（业务拓展）交易很热，我认为这只是一个开始。2026年，中国BD的水平肯定要再提高一步。 第三，我们有4个药物已经在准备提交新药临床试验许可，都是独一无二的同类首创药物，预计将在2026—2027年陆续进入临床开发。 此外，我们也会争取做更好、更大的BD。不过这不是自己说了算的，BD最终还是要靠管线说话。从这个方面讲，维立志博迟早会做大交易。以后在BD方 面，维立志博也会是中国创新药行业里比较重要的力量。 2026年，创新药的每个领域都会有比较明显的进展，有两个领域进展可能更明显： 第一个是小核酸药物，对慢性病来说它的临床效果确实比较好。 第二个是TCE（T细胞衔接器，一种免疫治疗药物）。免疫检查点抑制剂的双抗、三抗药物，也会更进一步，但我认为TCE进步对行业来说更重要。以前 TCE药物对实体瘤的作用不强，今年可能会有进展。比如，在小细胞肺癌上，TCE药物非常明显地延长了患者的总生存期，这是ADC（抗体偶联药物）难以 做到的。 2026年，维立志博的重点工作主要有以下三项，其中前两项围绕我们的核心管线LBL-024，也就是PD-1/41BB双抗。现在抗肿瘤免 ...

Core Insights - The Chinese innovative drug industry is entering a new decade of development in 2025, with a significant increase in business development (BD) transactions, reaching a total value of $135.655 billion and 157 transactions, both setting historical records, indicating the growing global appeal of Chinese innovative drugs [1] - Milestone payments from previously established collaborations are beginning to materialize, providing cash flow relief for companies and marking substantial progress in global development [1] - However, potential risks associated with BD collaborations are emerging, including the premature termination of agreements and disputes leading to arbitration or litigation, signaling a need for caution in the industry [1] Industry Trends - The surge in BD transactions in 2025 is driven by the long-accumulated innovative potential of China's biopharmaceutical sector, with expectations for continued growth in cross-border transactions between China and the US/Europe [2] - The BD trend began in 2022, but many companies have not yet experienced the full lifecycle of BD transactions, leading to potential undisclosed issues in long-term performance [2] - The period from 2026 to 2028 may see an increase in BD disputes, as the industry transitions from rapid growth to a more regulated and mature phase [2] Financial Highlights - In May 2025, a record-breaking upfront payment of $12.5 billion was secured by a collaboration between Sangamo Therapeutics and Pfizer, with potential total payments reaching $48 billion [3] - In July 2025, China National Pharmaceutical Group announced a $300 million milestone payment from Merck for a collaboration on a PD-1/VEGF dual antibody [3] - In October 2025, a $250 million milestone payment was triggered for a collaboration between SystImmune and Bristol-Myers Squibb, marking the largest single milestone payment for an ADC asset disclosed in China [3] Payment Structures - The "upfront payment + milestone + sales royalty" model remains the dominant approach for Chinese companies in BD transactions, but only 22% of biopharmaceutical companies achieved milestone events by mid-2025, a decrease from previous years [4] - Among 128 transactions with at least one milestone node, 45% did not generate any revenue, highlighting the uncertainty of milestone payment realizations [4] - Increasing the proportion of upfront payments to secure immediate cash flow has become a consensus among companies to mitigate risks [4] Contractual Strategies - Companies are advised to enhance negotiation strategies by creating competitive environments and optimizing milestone payment terms to reduce ambiguity and disputes [5][6] - Specific, quantifiable conditions for milestone payments should be established to minimize subjective interpretations and risks of disputes [5] - The interrelation of contractual terms should be considered to avoid imbalances in rights and obligations, which could lead to significant disagreements during project execution [6] Legal Considerations - The potential for a wave of litigation in the BD sector is rising, driven by long-term contracts and various uncertainties affecting performance [7] - Companies often prioritize commercial negotiations to resolve disputes, but if unsuccessful, they must rely on the agreed dispute resolution mechanisms, emphasizing the importance of precise contract language [7][8] - Early identification of dispute trajectories and effective crisis management can significantly influence the outcome of legal proceedings [8] Future Outlook - As of January 2026, 17 BD transactions have occurred, totaling $133.61 billion, with significant projects continuing to emerge [9] - The ADC sector, small nucleic acid drugs, and in vivo CAR-T therapies are expected to be key areas for BD transactions in the next 1-2 years, with a shift in focus towards clinical data validation [10] - The industry is moving towards a more mature and regulated phase, with an emphasis on risk awareness and compliance as essential elements for successful cross-border BD initiatives [10]

Core Insights - The strategic collaboration and licensing agreement between CSPC Pharmaceutical Group and AstraZeneca for the development of innovative long-acting peptide drugs has a potential transaction value of up to $18.5 billion, setting a new record for BD transactions among Chinese pharmaceutical companies [2][13]. Group 1: Transaction Details - The agreement includes an upfront payment of $1.2 billion and up to $17.3 billion in milestone payments [2][13]. - This transaction is part of a broader trend where multiple innovative drug BD transactions have been completed since the beginning of 2026, indicating a positive trend for Chinese innovative drugs going global [13][20]. Group 2: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has shown strong performance, leading its peers since 2025, with a return of 75.03% [4][17]. - The index is characterized by high purity, elasticity, and sharpness, demonstrating strong aggressiveness in the rebound of the innovative drug market [4][17]. Group 3: Historical Context - In 2025, the total value of innovative drug BD outbound licensing transactions from China reached $135.655 billion, with a total of 157 transactions, both setting historical highs [20][21]. - The historical annual returns for the Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index from 2021 to 2025 were -22.72%, -16.48%, -19.76%, -14.16%, and 66.32% respectively [6][18].

Core Viewpoint - The report from CITIC Securities indicates that while industrial production remains resilient and exports are growing rapidly, domestic demand indicators such as consumption and investment are still weak, highlighting a characteristic of "strong production versus weak demand" throughout the previous year [1] Economic Environment - The current macroeconomic environment shows similarities to the investment peak period of 2020-2021, with interbank interest rates at their lowest levels since 2020 [1] - The combination of weak macro demand and loose liquidity is expected to favor structural investment opportunities in certain sectors [1] Sector Insights - In the technology sector, AI semiconductors and new energy are identified as the core areas of current prosperity, with strong policy support for AI applications and accelerated commercialization [1] - The global capacity planning for space photovoltaics has exceeded expectations, and technological breakthroughs are opening up trillion-dollar markets [1] - The innovative drug sector is seeing value realization driven by business development transactions, clinical breakthroughs, and new drug approvals [1] Resource Sector - The non-ferrous metals industry has the highest forecasted performance improvement rate for 2025, with attention on the subsequent transmission of prosperity to the energy and machinery sectors [1] - As monetary easing continues, funds are expected to gradually shift from the financial system to the real economy, benefiting sectors such as non-ferrous metals, chemicals, machinery, and consumer goods [1] - Since December 2025, the South China Metal Index has risen by 12.5%, while the energy and industrial product indices have only increased by around 7%, suggesting better investment value in the current market [1]

Core Viewpoint - The collaboration between AbbVie and Rongchang Biologics marks a significant shift in the global oncology treatment landscape, highlighting the trend of Chinese innovative drug companies partnering with multinational giants for drug development and commercialization [1][2]. Group 1: Collaboration Details - AbbVie and Rongchang Biologics signed an exclusive licensing agreement for the development, production, and commercialization of RC148, a bispecific antibody targeting PD-1 and VEGF [1]. - Rongchang Biologics will receive an upfront payment of $650 million and is eligible for up to $4.95 billion in milestone payments, along with a tiered royalty on net sales outside Greater China [1][2]. Group 2: Market Implications - This deal exemplifies the "China innovation + global market" model, allowing Rongchang Biologics to secure cash flow and accelerate clinical trials for RC148 while focusing on the Chinese market [2]. - AbbVie aims to enhance its product portfolio in immuno-oncology, particularly in the emerging PD-1/VEGF bispecific antibody space, which could synergize with existing antibody-drug conjugates (ADCs) and immuno-oncology (IO) drugs [2]. Group 3: Competitive Landscape - The PD-1/VEGF bispecific antibody represents a new class of cancer therapies that may overcome tumor resistance mechanisms by simultaneously blocking PD-1 and VEGF [3][5]. - Chinese companies are leading in this field, with notable products like Ak112/Ivonescimab and SSGJ707 entering clinical trials, indicating a competitive landscape for PD-1/VEGF bispecific antibodies [3][4]. Group 4: Industry Trends - The surge in business development (BD) transactions in the PD-1/VEGF bispecific antibody sector reflects increasing interest from multinational pharmaceutical companies in Chinese innovative drug assets [6]. - In 2025, the total value of Chinese innovative drug licensing transactions exceeded $130 billion, surpassing the U.S. for the first time, indicating a significant shift in the global pharmaceutical landscape [7][8]. Group 5: Future Outlook - The increasing recognition of Chinese innovative drugs is attributed to their rapid development and the ability to meet unmet clinical needs, enhancing their bargaining power in international collaborations [8][9]. - The industry is witnessing a transition from following to leading in drug innovation, with a clear direction for the future of Chinese pharmaceutical development [10].

Core Insights - China's innovative drug transaction value has surpassed that of the United States, indicating growing global recognition of domestic innovations [1][4] - The total transaction amount for outbound licensing of innovative drugs from China is projected to reach $135.655 billion by December 31, 2025, with a significant increase in both upfront payments and transaction numbers compared to 2024 [1][4] - The surge in outbound licensing reflects the international community's acknowledgment of the value of Chinese innovative drugs, driven by reforms in drug approval processes and supportive policies [1][4] Transaction Overview - In 2025, the total amount of outbound licensing transactions for innovative drugs from China exceeded $1,300 billion, with over 150 transactions, significantly surpassing the 2024 figures of $519 billion and 94 transactions [4][5] - The first transaction of 2025 involved Innovent Biologics partnering with Roche, receiving an upfront payment of $80 million and potential milestone payments of up to $1 billion [4] - Notable transactions include a record upfront payment of $1.25 billion from 3SBio to Pfizer for a global licensing agreement, and a total transaction amount exceeding $12 billion with GSK [5] Market Dynamics - The demand for Chinese innovative assets is expected to persist as multinational corporations (MNCs) face patent cliffs and cost-cutting pressures [8][9] - The global pharmaceutical supply chain is undergoing significant adjustments, with MNCs increasingly looking to China for early-stage innovative pipelines due to cost-effectiveness and potential superior outcomes [9][10] - The shift in business development (BD) models is evident, with a move towards co-development and co-commercialization agreements, allowing Chinese companies to play a more active role in global markets [10][11] Industry Trends - China's innovative drug pipeline accounts for approximately 30% of the global total, with significant achievements in key therapeutic areas such as PD-1/VEGF bispecific antibodies [8] - The industry is transitioning from a "fast-follower" to a "first-in-class" model, emphasizing the importance of clinical value and unmet medical needs [6][15] - The approval of 76 innovative drugs in 2025, with a high percentage being domestically developed, highlights the growing capabilities of Chinese pharmaceutical companies [5][6] Future Outlook - The innovative drug sector in China is expected to face challenges in maintaining the momentum of BD transactions, with concerns about sustainability and the potential for a slowdown in transaction values [14][15] - The focus for 2026 will likely shift towards solidifying clinical value and addressing unmet needs, particularly in oncology and autoimmune diseases [15][16] - The Chinese regulatory body plans to implement more measures to support the rapid development of innovative drugs, indicating a commitment to fostering industry growth [15][16]

Core Viewpoint - China's innovative drug transaction value has surpassed that of the United States, indicating that domestic innovations are gradually gaining recognition in the global mainstream market [1][2]. Group 1: Transaction Data and Growth - By December 31, 2025, the total transaction amount for China's innovative drug business development (BD) overseas reached $135.655 billion (approximately 948.3 billion RMB), with an upfront payment of $7 billion and a total of 157 transactions, significantly exceeding the 2024 figures of $51.9 billion and 94 transactions [1][2]. - The total amount of overseas licensing for innovative drugs in China for 2025 is 2.5 times that of 2024 and 3.2 times that of the U.S. during the same period [2]. - The first transaction of 2025 involved Innovent Biologics partnering with Roche, receiving an upfront payment of $80 million and potential milestone payments of up to $1 billion [2]. Group 2: Notable Collaborations - In May 2025, 3SBio set a record for upfront payments in China by securing a global licensing agreement with Pfizer for $1.25 billion upfront and a total transaction value of $6 billion [3]. - Other significant collaborations include Heng Rui Medicine's partnership with GSK exceeding $12 billion and Innovent's collaboration with Takeda potentially reaching $11.4 billion [3]. Group 3: Industry Trends and Future Outlook - The surge in BD transactions is attributed to multinational corporations (MNCs) facing a "patent cliff" and cost-cutting pressures, increasing their demand for Chinese innovative assets [6][10]. - China's innovative drug pipeline accounts for approximately 30% of the global total, positioning the country as a significant player in key therapeutic areas such as PD-1/VEGF bispecific antibodies [6]. - The industry is transitioning from a "fast-follower" to a "first-in-class" or "best-in-class" model, emphasizing lean research and precise financing [4][10]. Group 4: Market Dynamics and Challenges - The global pharmaceutical supply chain is undergoing deep adjustments, and the valuation system is being restructured, presenting challenges for China's BD transactions [10]. - The industry is expected to face execution risks and potential disputes, with a consensus that while the BD boom will continue, the scale of transactions may not sustain the same explosive growth seen in 2025 [10][12]. - The focus for 2026 will shift towards solidifying clinical value and addressing unmet clinical needs, particularly in oncology and autoimmune disease sectors [10][12].

Core Viewpoint - The article highlights the unprecedented surge in business development (BD) activities in China's biotech sector, with the total amount of domestic innovative drug licensing exceeding $100 billion by November 18, 2025, marking a doubling compared to 2024. This trend reflects the increasing global competitiveness and value of Chinese pharmaceutical assets, while also prompting a deeper examination of transaction quality and product value realization post-agreement [1][2]. Summary by Sections BD Market Dynamics - The BD market in China is experiencing a significant boom, with a projected compound annual growth rate (CAGR) for external BD activities expected to remain in double digits over the next five years, despite a forecasted decline in growth rate [2]. - Key characteristics of future transactions include an increase in late-stage pipeline contributions and a shift from pure technology transfer to models involving "licensing + co-development + commercialization" [2]. Major Transactions - Notable transactions in 2025 include: - Hengrui Medicine's collaboration with GSK, involving a total potential amount of approximately $120 billion, with an upfront payment of $500 million [3]. - Innovent Biologics' agreement with Takeda, with a potential total of $114 billion and an upfront payment of $1.2 billion [3]. - A record-setting deal between 3SBio and Pfizer, with an upfront payment of $12.5 billion and potential milestone payments reaching $48 billion [5][6]. Global Interest in Chinese Biotech - Chinese innovative drugs are gaining significant traction in global markets, with multinational corporations increasingly sourcing early-stage innovation pipelines from China due to cost-effectiveness and potential efficacy [7][8]. - The trend indicates a shift where Chinese biotech firms are evolving from technology providers to value co-creators in the global pharmaceutical landscape [7]. Transaction Models - The dominant transaction model remains "License-out," which accounted for 91% of upfront payments and 99% of total amounts in related transactions in the first half of the year [10]. - NewCo models are gaining popularity, allowing companies to inject parts of their product pipelines into newly formed entities with foreign capital, reflecting a flexible asset operation strategy [10][11]. Future Outlook - The BD market is expected to continue thriving, driven by the need for multinational companies to replenish their pipelines as many blockbuster drugs face patent expirations, creating a significant market opportunity [15]. - Emerging technologies, particularly in ADCs and bispecific antibodies, are anticipated to dominate future BD transactions, with a notable interest in metabolic and autoimmune products [16][17]. Challenges and Considerations - Despite the growth, challenges remain in ensuring compliance with international standards and protecting intellectual property during global collaborations [13]. - The market is expected to stabilize, with a rational return to expectations regarding BD transactions, as the industry matures and the focus shifts from explosive growth to sustainable value creation [17].

Core Viewpoint - The Hong Kong stock market experienced a strong upward trend in 2025, with the Hang Seng Index rising by 27.77% and the Hang Seng Tech Index increasing by 23.45%, driven by active trading and improved market sentiment [1][12]. Market Performance - The trading volume in the Hong Kong stock market significantly increased compared to previous years, indicating heightened trading activity and a broad release of market profit potential [1]. - The year saw a clear phase rotation in the market, with different sectors driving the market's upward movement at various times, including AI technology, innovative pharmaceuticals, and non-competitive policies leading to industrial optimization [3][5]. Sector Analysis - The technology sector was a major player in the market, with the Hang Seng Tech Index rising by 20.74% in Q1 2025, outperforming the Hang Seng Index's 15.25% increase during the same period [4]. - The innovative pharmaceutical sector gained momentum due to a surge in business development (BD) transactions, benefiting from improved global liquidity as the Federal Reserve began its rate-cutting cycle [4][5]. - The metals sector, particularly non-ferrous metals, emerged as the strongest performer by year-end, with copper stocks rising by 261.85%, gold and precious metals by 197.85%, and other metals and mining stocks by 187.91% [6][7]. Individual Stock Performance - Notable individual stock performances included Zijin Mining (02899.HK) rising by 162%, Shandong Gold (01787.HK) increasing by over 183%, and Jiangxi Copper (00358.HK) climbing nearly 281% [9]. - The stock of珠峰黄金 (01815.HK) skyrocketed by over 1286%, marking it as a rare "tenfold" stock in a year [9]. Investment Drivers - The rise in non-ferrous metals was attributed to multiple favorable factors, including the global trend of "de-dollarization," supply-demand imbalances in industrial metals, and domestic policies optimizing supply structures [6][10]. - The rapid development of emerging industries such as AI, new energy, and innovative pharmaceuticals provided a wealth of high-growth investment opportunities, supporting long-term stock price increases [12][13]. Future Outlook - Analysts expect the Hong Kong stock market to continue its upward trend in 2026, driven by improved liquidity and corporate profit recovery, with a potential shift in market driving logic from valuation recovery to profit growth [13].